Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2414578 | 1.00 | GCK (0.49) | GCKMAPTTHRB | |
| SCHEMBL2414572 | 1.00 | GCK (0.49) | GCKMAPTTHRB | |
| SCHEMBL2411869 | 0.90 | GCK (0.49) | GCK | |
| SCHEMBL2416789 | 0.90 | GCK (0.49) | GCK | |
| SCHEMBL2411864 | 0.90 | GCK (0.49) | GCK | |
| SCHEMBL2416790 | 0.90 | GCK (0.49) | GCK | |
| SCHEMBL2416785 | 0.90 | GCK (0.49) | GCK | |
| SCHEMBL2411868 | 0.90 | GCK (0.49) | GCK | |
| SCHEMBL2409165 | 0.89 | GCK (0.61) | GCK | |
| SCHEMBL2409166 | 0.89 | GCK (0.61) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2508513-A1 | 2-PYRIDONE COMPOUNDS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| EP-2508513-A1 | 2-PYRIDONE COMPOUNDS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2011068211-A1 | 2-PYRIDONE COMPOUNDS | 大正製薬株式会社 (JP) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | PDXK, HK1, KCNJ2 | GCK 4/4885MAPT 532/4885THRB 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.